ZEO ScientifiX to Expand Regenerative Medicine Operations into Georgia and Tennessee After New State Laws Take Effect
核心洞察
ZEO ScientifiX (搜索) announced plans to expand its regenerative biologics and provider-support operations into Georgia and Tennessee following enactment of new state regenerative medicine laws.
Georgia House Bill 1275 was signed on May 11, 2026, and Tennessee House Bill 2246 on May 19, 2026, establishing state-level frameworks for qualifying therapies.
Tennessee's framework expressly includes certain exosome-based regenerative products within its definition of regenerative medicine therapy (搜索) when statutory product and manufacturing criteria are met.
ZEO ScientifiX (搜索), Inc. (OTCQB:ZEOX) announced on September 15, 2026 that it plans to expand into Georgia and Tennessee, following the recent enactment of state laws in each jurisdiction establishing frameworks for certain stem cell and regenerative medicine therapies. The company said the expansion advances its strategy to support healthcare professionals across the Southeast with regenerative biologics, scientific resources, physician education, and responsible implementation support.
The move builds on ZEO ScientifiX (搜索)'s existing work with healthcare professionals in Florida who have sought to take advantage of a new Florida law passed in 2025, as well as the company's broader national growth strategy.
State Legislative Frameworks
Georgia House Bill 1275 was signed into law on May 11, 2026, and Tennessee House Bill 2246 was signed into law on May 19, 2026. According to the company, both laws establish state-level requirements under which qualifying therapies may be performed by authorized healthcare professionals.
The laws include provisions addressing product sourcing and documentation, patient disclosures and informed consent, professional scope of practice, and safety oversight. Tennessee's framework expressly includes certain exosome-based regenerative products within its definition of regenerative medicine therapy (搜索) when statutory product and manufacturing criteria are met.
ZEO ScientifiX (搜索) emphasized that the state laws do not constitute approval by the U.S. Food and Drug Administration (搜索) and do not displace applicable federal law. Providers remain responsible for determining whether a therapy, product, advertisement, and clinical protocol comply with all applicable federal and state requirements, professional licensing rules, and standards of care.
Commercial and Provider-Support Plans
ZEO ScientifiX (搜索) said it is planning to expand its commercial and provider-support presence in Georgia and Tennessee to serve healthcare professionals operating within the states' evolving regulatory environments. The company expects to support market development through provider education, product support, clinical collaboration, and access to regenerative biologics accompanied by quality and manufacturing documentation appropriate to the applicable product and jurisdiction.
"Expansion into Georgia and Tennessee represent an important next step in the growth of regenerative medicine across the Southeast," said Ian Bothwell, CEO of ZEO ScientifiX (搜索). "As more states develop frameworks for responsible physician-led access, ZEO is prepared to expand alongside them. Our goal is to earn the trust of healthcare professionals by pairing high-quality biologics with scientific transparency, education, and the operational support needed to navigate a rapidly changing field."
Positioning Within South Florida's Biotechnology Sector
The expansion follows the company's efforts to strengthen its role in South Florida's healthcare innovation ecosystem. ZEO ScientifiX (搜索) operates from Nova Southeastern University's Center for Collaborative Research in Davie, Florida, a setting the company describes as placing it in proximity to a broader community of researchers, healthcare professionals, and scientific innovators.
A central component of the company's strategy is strengthening the connection between scientific advancement and physician education. As interest in regenerative medicine expands across multiple medical specialties, ZEO ScientifiX (搜索) has increased investment in educational initiatives designed to help healthcare professionals better understand the evolving science, clinical considerations, and responsible integration of regenerative biologics. These initiatives include physician Master Classes, educational webinars, scientific programming, professional collaborations, and continued development of the company's Medical Advisory Board, which brings together experienced physicians from multiple specialties.
"Scientific advancement alone is not enough," said Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX (搜索). "For an emerging field to advance responsibly, physicians need access to credible education, meaningful scientific dialogue, and opportunities to learn from experts across disciplines. Building that infrastructure is an important part of what we believe ZEO can contribute to this industry."
Bothwell framed the regional environment as foundational to the company's growth. "Florida has become an increasingly important center for the life sciences industry, supported by significant university research investment, a growing biotechnology workforce, and an expanding network of healthcare companies and research institutions," he said. "South Florida, in particular, has developed into a dynamic healthcare and biotechnology corridor, attracting physicians, researchers, entrepreneurs, and companies from across the country. For ZEO ScientifiX (搜索), that environment provides an important foundation for the Company's continued growth and long-term vision."
Vega-Stanton added that the company views the opportunity as extending beyond its own operations: "South Florida has the ingredients necessary to become one of the most influential biotechnology and regenerative medicine ecosystems in the country. The opportunity goes far beyond simply building a biotechnology company here. It is about creating an environment where scientists, physicians, educators, and industry leaders can work together to responsibly move the field forward. ZEO intends to be an active part of building that future."
Company Profile
ZEO ScientifiX (搜索), Inc. (OTCQB:ZEOX) describes itself as an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University's Center for Collaborative Research, the company states that it translates emerging science into scalable clinical solutions and supplies clinicians seeking to drive clinical excellence and sustainable practice growth through its biologics and regenerative therapies.
The company said it intends to continue expanding its scientific and educational initiatives, strengthening relationships across the medical community, and supporting responsible advancement within the regenerative medicine field.